Genebank - Funding Core Activities (2017-2021) Philip Chiverton - - PowerPoint PPT Presentation

genebank funding
SMART_READER_LITE
LIVE PREVIEW

Genebank - Funding Core Activities (2017-2021) Philip Chiverton - - PowerPoint PPT Presentation

Genebank - Funding Core Activities (2017-2021) Philip Chiverton Chair Peer Review Team (PRT) Background FC 12: Discussion on value of genebanks and need for a continuation plan. FC 13: Agreement on 2017-2021 support. Genebank Option


slide-1
SLIDE 1

Genebank - Funding Core Activities (2017-2021)

Philip Chiverton Chair Peer Review Team (PRT)

slide-2
SLIDE 2

Background

  • FC 12: Discussion on value of genebanks and need for a continuation plan.
  • FC 13: Agreement on 2017-2021 support.

 Genebank Option Paper,  PRT recommendations,  FC decision to commit $93.1m for the period 2017-2021,  Blended approach to funding,  Need for a Levy for “relevant CRPs”,  PRT tasked to explore different solutions and report at FC14.

  • FC14: Reach agreement on optimal levy model
slide-3
SLIDE 3

Relevant CRPs?

  • 2014

Budget ($m)

  • W1/2

W3 Bil W3/Bil Total WHEAT 17.2 7.9 13.6 21.5 38.7 MAIZE 19.1 13.3 27.9 41.2 60.3 GRiSP (Rice) 35.2 23.6 35.1 58.7 93.9 Roots, Tubers & Bananas 31.1 20.3 23.7 44 75.1 Grain Legumes 16.4 13.3 16.3 29.6 46.0 Dryland Cereals 8.6 5.6 7.2 12.8 21.4 Forests, Trees, Agroforestry 30.4 12.4 35.6 48 78.4 Total 158 96.4 159.4 255.8 413.8

slide-4
SLIDE 4

Principles (today)

slide-5
SLIDE 5

Principles (2017-2021)

slide-6
SLIDE 6

Modeling different levies

Budget as of 2014 Different Levies ONLY Window 3/Bilateral

slide-7
SLIDE 7

Modeling different levies

Budget as of 2014 Different Levies Including Window 2 = (W2, 3 + bilateral)

slide-8
SLIDE 8

Refining options…

  • Taking into consideration that Window 1 contribution to the Genebank

programme is a safety net, other sources of funding (e.g. CRP line item for genebanks support) should represent the majority of the contribution (i.e. greater that 50%).

  • It is also assumed that in no circumstances, the income generated

from CRPs should exceed the amount required to support the Genebank programme.

slide-9
SLIDE 9

Refining options…

slide-10
SLIDE 10

Modeling (2017-2021)

15.7 12.8 8.5 4.3 0.8

  • 5.0

10.0 15.0 20.0 25.0 30.0 2017 2018 2019 2020 2021 16.1 13.2 8.9 4.7 1.2 5 10 15 20 25 30 2017 2018 2019 2020 2021

4% Levy on Window 3 and bilateral funds 3% Levy on Window 2, 3 and bilateral funds Levy contribution Window 1 ‘Safety Net’

slide-11
SLIDE 11

Post-2021

GCDT – Endowment ≈ 80% CGIAR Fund + Levy ≈ 20%

slide-12
SLIDE 12

Post-2021

16.1 13.2 8.9 4.7 1.2 5 10 15 20 25 30 2017 2018 2019 2020 2021

3% Levy on Window 2, 3 and bilateral funds Levy contribution

2022

3% Levy on Window 2, 3 and bilateral May exceed the required funding from the CGIAR Fund to the Genebank Programme

slide-13
SLIDE 13

Recommendations

  • 1. The Fund Council is invited to approve a Genebank levy on relevant

CRPs of a minimum of 3% on Window 2, 3 and bilateral funds only applicable to relevant CRPs, which should be, included as a line item in relevant CRP budgets.

  • 2. The Fund Office and Consortium Office should be invited to confirm

the list of ‘relevant CRPs’ within the new CRP portfolio and provide more accurate financial projections by end of 2016, based on the final CRP 2nd Call proposals budget approved at the end of 2016 by the Council.

  • 3. The Fund Council may want to consider a possible reduction of such

levy from 3% to 2% post 2021 conditional on effective collection of the proposed levy during the period 2017-2021 (and confirmation from the Trust Endowment post 2021 contribution).